Maze Therapeutics, Inc. MAZE
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly-owned clinical programs, MZE829 and MZE782.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | — | $167.5M | — |
| R&D | $108.4M | $83.5M | — |
| SG&A | $34.5M | $26.4M | — |
| Total operating expenses | $142.9M | $109.9M | — |
| Operating income | -$142.9M | $57.6M | — |
| Pre-tax income | -$131.1M | $53.4M | — |
| Income tax | $0 | $1.2M | — |
| Net income | -$131.1M | $52.2M | — |
| EPS, basic | -3.05 | 1.42 | — |
| EPS, diluted | -3.05 | 1.25 | — |
| Shares, diluted (wtd. avg.) | 43.0M | 2.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $189.2M | $196.8M | $30.2M |
| Short-term investments | $152.7M | — | — |
| Total current assets | $349.7M | $201.7M | — |
| Property, plant and equipment | $5.0M | $6.7M | — |
| Total assets | $397.1M | $240.5M | — |
| Accounts payable | $1.8M | $1.9M | — |
| Total current liabilities | $22.6M | $20.7M | — |
| Total liabilities | $42.2M | $43.6M | — |
| Retained earnings | -$489.5M | -$358.4M | — |
| Total equity | $355.0M | -$311.2M | -$373.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$111.9M | $76.0M | — |
| Depreciation and amortisation | $2.4M | $3.3M | — |
| Stock-based compensation | $16.4M | $9.6M | — |
| Capital expenditure | $794.0K | $1.1M | — |
| Investing cash flow | -$171.0M | -$1.1M | — |
| Financing cash flow | $275.3M | $92.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-122778.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $167.5M | — |
| Gross profit | — | — | — |
| Net income | — | $52.2M | -$131.1M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |